ストックスクリーナーアプリを入手
2.93
2.45%
0.07
アフターアワーズ：
2.97
0.04
+1.37%
Fortress Biotech Inc (FBIO) 最新ニュース
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
FBIOP Q4 2025 Earnings: Preferred Stock Faces EPS Miss as Company Reports LossEPS Revision Trend - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet SessionProtective Put - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key SupportDescending Triangle - newsline.com
Price-Driven Insight from (FBIOP) for Rule-Based Strategy - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of - AD HOC NEWS
Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5BPI Bear Confirmed - newsline.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO) - Seeking Alpha
FBIO Q4 2025 Earnings: EPS Misses Estimates, Stock Moves HigherEarnings Quality Analysis - newsline.com
FBIO Q4 2025 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Seasonality - The Legal Advocate
Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in FocusSynthetic Long - The Legal Advocate
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise - Investing.com Canada
FBIOP Q4 2025 Earnings: Preferred Stock Reports Negative EPS Surprise Amid No Revenue Disclosure - newsline.com
Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16Dark Pool Prints - The Legal Advocate
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelLarge Cap Trends - The Legal Advocate
FBIO Q4 2025 Earnings: Significant EPS Surprise Miss Amid Limited Revenue DisclosureOne-Time Loss Impact - newsline.com
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongInterim Report - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech (FBIO) Q1: EPS $2.82 Beats Est. -$0.22; Revenue - GuruFocus
Fortress Biotech Q1 2026 Earnings Call Transcript - MarketBeat
Fortress Biotech: Q1 Earnings Snapshot - marketscreener.com
Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82— 10-Q Summary - TradingView
Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M - TradingView
Priority review voucher sale drives Fortress Biotech (FBIO) Q1 2026 profit and cash surge - Stock Titan
Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale - Stock Titan
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum - AD HOC NEWS
FBIO: Q1 2026 revenue rose 21% to $16M, driven by EMROSI growth and expanding market access - TradingView
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - marketscreener.com
(FBIOP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):